Melanoma immunotherapy

Shanthi Sivendran, Bradley Glodny, Michael Pan, Miriam Merad, Yvonne Saenger

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Melanoma immunotherapy has been an area of intense research for decades, and this work is now yielding more tangible results for patients. Work has focused on 4 main areas: cytokine therapy, administration of immune-modulating antibodies, adoptive T-cell therapy, and vaccines. Cytokine therapy is an established treatment for advanced melanoma, and immune-modulating antibodies have recently emerged as an exciting new area of drug development with efficacy now established in a phase III trial. Adoptive T-cell therapy provides the proof of principle that T cells can attack and eliminate tumors. It has been challenging, however, to adapt this treatment for widespread use. Vaccines have generally yielded poor results, but intratumor pathogen-based strategies have shown encouraging results in recent trials, perhaps due to stronger immune stimulation. A review of the field of melanoma immunotherapy is provided here, with emphasis on those agents that have reached clinical testing. Novel strategies to induce the immune system to attack melanomas are reviewed. In the future, it is envisioned that immunotherapy will have further application in combination with cytotoxic and targeted therapies.

Original languageEnglish (US)
Pages (from-to)620-642
Number of pages23
JournalMount Sinai Journal of Medicine
Volume77
Issue number6
DOIs
StatePublished - Nov 2010
Externally publishedYes

Keywords

  • antibody
  • cytokine
  • immunotherapy
  • melanoma
  • vaccine

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Melanoma immunotherapy'. Together they form a unique fingerprint.

Cite this